J D Mitchell

Summary

Affiliation: Royal Preston Hospital
Country: UK

Publications

  1. ncbi Amyotrophic lateral sclerosis
    J D Mitchell
    Motor Neurone Disease Care and Research Centre, Royal Preston Hospital, Fulwood, Preston PR2 9HT, UK
    Lancet 369:2031-41. 2007
  2. ncbi Rasch analysis of the hospital anxiety and depression scale (HADS) for use in motor neurone disease
    Chris J Gibbons
    Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool, UK
    Health Qual Life Outcomes 9:82. 2011
  3. ncbi Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)--a 20-year review: can we do better?
    John Douglas Mitchell
    Preston MND Care and Research Centre, Royal Preston Hospital, Sharoe Green Lane, Preston, UK
    Amyotroph Lateral Scler 11:537-41. 2010
  4. ncbi Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis
    G M Kiebert
    MEDTAP International, 20 Bloomsbury Square, London, UK
    J Neurol Sci 191:87-93. 2001
  5. ncbi Quality of life in motor neurone disease--towards a more practical assessment tool?
    J D Mitchell
    J Neurol Neurosurg Psychiatry 74:287-8. 2003
  6. ncbi Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
    R G Miller
    Department of Neurology, California Pacific Medical Center, San Francisco, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 4:191-206. 2003
  7. ncbi Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis
    C Green
    Wessex Institute for Health Research and Development, Boldrewood, University of Southampton, Southampton, UK
    Qual Life Res 12:565-74. 2003
  8. ncbi Effect of referral bias on assessing survival in als
    G Logroscino
    Neurology 69:939; author reply 939-40. 2007
  9. ncbi Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues
    G Logroscino
    Department of Epidemiology HSPH 3 819 Harvard University, 677 Huntington Avenue, Boston, Massachusetts 02115, USA
    J Neurol Neurosurg Psychiatry 79:6-11. 2008

Collaborators

Detail Information

Publications9

  1. ncbi Amyotrophic lateral sclerosis
    J D Mitchell
    Motor Neurone Disease Care and Research Centre, Royal Preston Hospital, Fulwood, Preston PR2 9HT, UK
    Lancet 369:2031-41. 2007
    ..We conclude with an overview of some current major issues and future prospects, ranging from the search for disease markers to challenging developments such as stem-cell and gene therapy...
  2. ncbi Rasch analysis of the hospital anxiety and depression scale (HADS) for use in motor neurone disease
    Chris J Gibbons
    Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool, UK
    Health Qual Life Outcomes 9:82. 2011
    ..This study seeks to analyse the construct validity of the HADS in MND by fitting its data to the Rasch model...
  3. ncbi Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)--a 20-year review: can we do better?
    John Douglas Mitchell
    Preston MND Care and Research Centre, Royal Preston Hospital, Sharoe Green Lane, Preston, UK
    Amyotroph Lateral Scler 11:537-41. 2010
    ..Educational interventions among health care professionals both in primary and secondary care may also help shorten diagnostic pathways...
  4. ncbi Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis
    G M Kiebert
    MEDTAP International, 20 Bloomsbury Square, London, UK
    J Neurol Sci 191:87-93. 2001
    ..37 for stage 4 (late stage) disease severity. Utilities elicited via SG were systematically higher than VAS scores and ranged from a mean of 0.79 for stage 1 disease severity to a mean of 0.45 for stage 4 disease severity...
  5. ncbi Quality of life in motor neurone disease--towards a more practical assessment tool?
    J D Mitchell
    J Neurol Neurosurg Psychiatry 74:287-8. 2003
  6. ncbi Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
    R G Miller
    Department of Neurology, California Pacific Medical Center, San Francisco, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 4:191-206. 2003
    ..Riluzole has been approved for treatment of patients with amyotrophic lateral sclerosis in many countries but not all. Questions persist about its clinical utility because of high cost, modest efficacy and concern over adverse effects...
  7. ncbi Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis
    C Green
    Wessex Institute for Health Research and Development, Boldrewood, University of Southampton, Southampton, UK
    Qual Life Res 12:565-74. 2003
    ..This study demonstrates that it is feasible and practical to obtain health state values from MND patients and it provides evidence that patients place a high value on their HRQL, even in cases where health status is very poor...
  8. ncbi Effect of referral bias on assessing survival in als
    G Logroscino
    Neurology 69:939; author reply 939-40. 2007
  9. ncbi Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues
    G Logroscino
    Department of Epidemiology HSPH 3 819 Harvard University, 677 Huntington Avenue, Boston, Massachusetts 02115, USA
    J Neurol Neurosurg Psychiatry 79:6-11. 2008
    ....